1
play

1 PMH PMH Medical HxP: Pregnancy: Normal, no drugs taken - PDF document

Objectives Pediatric Pulmonary Arterial Hypertension: Case Presentation Case presentation Brief review of the topic Review of the literature- issues surrounding the case Susan Richards RN, MN, NP Pediatric Pulmonary Hypertension,


  1. Objectives Pediatric Pulmonary Arterial Hypertension: Case Presentation • Case presentation • Brief review of the topic • Review of the literature- issues surrounding the case Susan Richards RN, MN, NP Pediatric Pulmonary Hypertension, Stollery Children’s Hospital 2 Case Presentation HPC • January 15 2018: History of coughing since January 10 • J.K. , 4/12 male 2018, greyish appearance prior to this time. CXR: suggestive for cardiac enlargement. No pulmonary disease. • January 21 2018: Cardiac enlargement; no pulmonary PC disease. Desaturations into low 80’s (responsive to O2). • Peripheral and central cyanosis. Sats okay with • January 22 2018: Transferred to Stollery Children's supplemental O2 4L. Mod to severe resp. distress Hospital ER. – Resp Distress – FTT (3.5kg) – Sats okay on 4L NC 3 4 1

  2. PMH PMH • Medical HxP: • Pregnancy: Normal, no drugs taken – G6PC3 deficiency • Perinatal/Delivery: SVD, no complications, 2100grams (approx 4lbs 10 oz) – ASD • Postnatal: 24 hours post delivery cyanotic (Sats low – Undescended testicles 70%), RR 100, normal BS, septic workup, abx – Small for gestational age – 0.00 neutrophil – Osteopetrosis – WBC 0.8 – FTT – NP aspirate: + Human metapneumovirus • Med: G-CSF • Allergies: NKA • Immunizations: none 5 6 FH/SH O/E • General: Alert, irritable with examination, • First Child adequate head control. Wt 3.6kg /Ht: 59 cm • Caucasian • CNS: Anterior fontanelle soft • No one in family with known genetic defect • Resp: 40-50 mild in-drawing; suprasternal, tracheal tug. • No Hx of consanguinity Cry, squeaky but audible 2L O2 • Parents healthy (young) • CVS: WWP centrally; cool extremities.HR 109-157 SR;S2 split with increase P2; mild RV heave • Lives in a Hutterite Colony Rural Alberta • Abdomen: Liver 1 cm below RCM GU: undescended • No recent travel testes • Skin: superficial venous angiectasis 7 8 2

  3. CXR ECG 9 10 ECHO Investigations • CXR: Cardiac Enlargement; lung and pleural spaces clear • ECG: SR, RAE, RVH, and LVH by voltage; towards RAD • Echocardiogram: small secundum ASD; bidirectional shunting RVSp 74 mmHg+Rap (SBP 98mmHg); PR mean PAp 32 mmHg; RVFAC 13%; small pericardial effusion. • Blood work: WBC 34.1; Neut.,30.2; ALT 72; NTproBNP 1624.0 pmol/L; Blood Culture,neg; NP aspirate;+ Human metapnemovirus &entero-rhinovirus; • MRSA, neg 11 12 3

  4. Management Pro Beta Natriuretic Peptide NT proBNP • Echocardiogram assessing pulmonary veins. Test Number 1 2 3 4 5 • Start sildenafil 0.25 mg/kg x2 doses. Then 0.5 mg/kg x2 Collection Date 24-Jan-18 02-Feb-18 08-Feb-18 21-Feb-18 13-Mar-18 doses, and then 1 mg/kg per dose q8h pmol/L 1624.0 162.5 67.3 92.7 211.1 1800 • Aldactazide1mg/kg BID. 1600 1400 • Add in ETA 1200 1000 • Hematology to follow neutropenia 800 600 400 200 0 1 2 3 4 5 13 14 G6P Classification G6PC3 Pathophysiology General Points • Glucose-6-phosphatase enzyme is located in the endoplasmic reticulum (ER) and hydrolyses glucose-6- • Genetic disease autosomal recessive mutations on phosphate to glucose and phosphate. 17q21.31 • Loss of G6PC3 function shown to result in prevention of • Member of G6P family glucose recycling from the ER to the cytoplasm in the – G6PC1 (liver, gut and kidney) neutrophil – G6PC2 (pancreas) • Loss of G6PC3 activity also shown to increased • G6PC3 ubiquitously: Features congenital neutropenia, susceptibility to apoptosis in skin fibroblasts, superficial skin venous pattern heart and urogenital, neutrophils, and myeloid cells SHNL, FTT,PAH, cognitive impairment and/or endocrine abn 15 16 4

  5. Pathophysiology Con’t G6PC3 Deficiency • Identification of the genetic basis of Dursun syndrome • Mutations in G6PC3 cause SCN4. adds to the existing knowledge that mutations in G6PC3 • Recurrent infections and prominent superficial venous can cause PPH. pattern are the most frequent clinical features • PPH is a known complication of type 1 glycogen • Congenital heart defects and urogenital malformations storage and establishing PPH as part of SCN4 • Dursun syndrome is triad of familial PPH, leucopenia, phenotype may suggests an important link between and ASD. glucose metabolism and PPH. • Dursun syndrome expands the pre-existing knowledge • Further studies needed of the phenotypic effects of mutations in G6PC3 • Should Dursun syndrome be considered as a subset of SCN4 with PPH as an important clinical feature? 17 18 Management/Challenges References • Treatment with G-CSF • Boztug, K.,et al. A syndrome with congenital neutropenia and mutations in G6PC3. New Eng. J. Med . 360: 32- 43, 2009. • Bacterial and viral infections • McDermott, D. H., et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood 116: 2793-2802, 2010. • Pulmonary vasodilator (s) • Arikoglu, T., et al. A novel G6PC3 gene mutation in severe congenital neutropenia: pancytopenia and variable bone marrow phenotype can also be part of this syndrome. European Journal of Hematology . 94: 79-82, 2014. • Banka, S. & Newman, W. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency • Timing of images and invasive procedures caused by G6PC3 mutations. Journal of Rare Diseases . 8:84 1-17, 2013. • Banka, S., et al. Mutations in the G6PC3 Gene Cause Dursun Syndrome. American Journal of Medical Genetics . • Size of ASD 52A:2609–2611, 2010 • Lammers, A. et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary • No immunizations hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis andtreatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease. • Medication compliance Heart BMJ . 102:ii1-ii13, 2016. • Kozlik-Feldmann, R., et al. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary • Multidisciplinary team approach hypertension. The European Paediatric Pulmonary Vascular Disease. Heart BMJ . 102:ii42-ii48, 2016. 19 20 5

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend